EcoR1 Capital’s CytomX Therapeutics CTMX Stock Holding History

EcoR1 Capital’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,101	Closed	-$8K	–	53
2020 Q1	$8K	Sell	1,101 -408,899	-100%	-$2.85M	﹤0.01%	51
2019 Q4	$3.41M	Buy	+410,000	New	+$2.77M	0.31%	41
2017 Q4	–	Sell	-829,771	Closed	-$15.1M	–	34
2017 Q3	$15.1M	Buy	829,771 +34,802	+4%	+$543K	2.01%	13
2017 Q2	$12.3M	Hold	794,969	–	–	2.19%	11
2017 Q1	$13.7M	Buy	+794,969	New	+$10.5M	3.47%	9

Other funds holding CTMX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

EcoR1 Capital's CTMX Position: Q2 2020 in Review

EcoR1 Capital sold out of CytomX Therapeutics (CTMX) in Q2 2020, closing a stake of 1,101 shares — an estimated $8K sold.

EcoR1 Capital first reported a position in CTMX in Q1 2017 and held it in 5 quarters. The position peaked at $15.1M in Q3 2017. 134 funds tracked by Wall St. Rank hold CTMX as of Q2 2020.

EcoR1 Capital reported no remaining CytomX Therapeutics position as of Q2 2020 after selling out during the quarter.
EcoR1 Capital sold 1,101 CytomX Therapeutics shares in Q2 2020, an estimated $8K.
EcoR1 Capital first reported a position in CytomX Therapeutics in Q1 2017 and held it in 5 quarters.
EcoR1 Capital's CytomX Therapeutics position peaked at $15.1M in Q3 2017.
134 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2020.

Based on EcoR1 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.